Technological advances in the monitoring of glucose and delivery of insulin for diabetes patients has led JP Morgan analyst Robbie Marcus to upgrade shares of Dexcom to " overweight " and raise his price target on the firm from $ 80 to $ 115 . US firm Dexcom makes continuous glucose monitoring devices ( CGM ) that attach to a patient 's skin , and treatment is moving in the direction of insulin pumps that link insulin dosage to CGMs , Marcus said . Dexcom 's system also provides tools that connect to phones and share data with healthcare providers , CEO Kevin Sayer explained . Dexcom 's share price has risen 62 % this year .
Technological advances in the monitoring of glucose and dosing of insulin for diabetes patients has led JP Morgan analyst Robbie Marcus to upgrade shares of Dexcom to "overweight" and raise his price target on the firm from $80 to $115. US firm Dexcom makes continuous glucose monitoring devices (CGM) that attach to a patient's skin, and treatment is moving in the direction of integrated pumps that link insulin dosage to CGMs, Marcus said. Dexcom's system also provides tools that connect to phones and share data with treatment providers, CEO Kevin Sayer explained. Dexcom's share price has risen 62% this year.